Symbols / GLSI Stock $22.21 -2.59% Greenwich LifeSciences, Inc.

Healthcare • Biotechnology • United States • NCM
GLSI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Snehal S. Patel
Exch · Country NCM · United States
Market Cap 307.71M
Enterprise Value 312.08M
Income -19.48M
Sales —
FCF (ttm) -1.36M
Book/sh 0.16
Cash/sh 0.28
Employees 4
Insider 10d —
IPO Sep 25, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -27.09
PEG —
P/S —
P/B 140.57
P/C —
EV/EBITDA -15.94
EV/Sales —
Quick Ratio 2.35
Current Ratio 2.35
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.46
EPS next Y -0.82
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2025-11-14
ROA -254.19%
ROE -5.43%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 13.85M
Shs Float 6.57M
Insider Own 50.71%
Instit Own 11.02%
Short Float 22.19%
Short Ratio 9.12
Short Interest 1.52M
52W High 34.10
vs 52W High -34.87%
52W Low 7.78
vs 52W Low 185.48%
Beta 1.53
Impl. Vol. —
Rel Volume 0.34
Avg Volume 173.19K
Volume 59.73K
Target (mean) $47.50
Tgt Median $47.50
Tgt Low $45.00
Tgt High $50.00
# Analysts 2
Recom Strong_buy
Prev Close $22.80
Price $22.21
Change -2.59%
About

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$47.50
Mean price target
2. Current target
$22.21
Latest analyst target
3. DCF / Fair value
$-1.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$22.21
Low
$45.00
High
$50.00
Mean
$47.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-30 main HC Wainwright & Co. Buy → Buy $50
2025-04-21 main HC Wainwright & Co. Buy → Buy $39
2025-02-11 reit HC Wainwright & Co. Buy → Buy $38
2024-08-23 main HC Wainwright & Co. Buy → Buy $38
2024-05-22 reit HC Wainwright & Co. Buy → Buy $36
2024-02-28 reit HC Wainwright & Co. Buy → Buy $36
2024-02-20 main HC Wainwright & Co. Buy → Buy $36
2023-04-10 reit HC Wainwright & Co. — → Buy $38
2021-09-01 init HC Wainwright & Co. — → Buy $78
2021-01-27 init Aegis Capital — → Buy $75
2021-01-26 init Aegis Capital — → Buy $75
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-13 PATEL SNEHAL Chief Executive Officer — 1,800 $29.83 $53,694
2026-01-12 PATEL SNEHAL Chief Executive Officer — 2,900 $27.54 $79,866
2025-12-31 PATEL SNEHAL Chief Executive Officer — 4,300 $21.36 $91,848
2025-12-30 PATEL SNEHAL Chief Executive Officer — 2,900 $21.73 $63,017
2025-12-18 PATEL SNEHAL Chief Executive Officer — 4,100 $12.62 $51,742
2025-11-25 PATEL SNEHAL Chief Executive Officer — 4,600 $8.37 $38,502
2025-11-07 PATEL SNEHAL Chief Executive Officer — 10,600 $8.43 $89,358
2025-10-31 PATEL SNEHAL Chief Executive Officer — 2,300 $9.26 $21,298
2025-04-25 PATEL SNEHAL Chief Executive Officer — 3,600 $9.88 $35,568
2025-04-17 PATEL SNEHAL Chief Executive Officer — 5,400 $8.98 $48,492
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
16.01
+71.66%
9.33
+16.01%
8.04
+74.87%
4.60
Research And Development
12.95
+68.24%
7.70
+18.89%
6.48
+81.93%
3.56
Selling General And Administration
3.06
+87.80%
1.63
+4.13%
1.56
+50.67%
1.04
General And Administrative Expense
3.06
+87.80%
1.63
+4.13%
1.56
+50.67%
1.04
Other Gand A
3.06
+87.80%
1.63
+4.13%
1.56
+50.67%
1.04
Total Expenses
16.01
+71.66%
9.33
+16.01%
8.04
+74.87%
4.60
Operating Income
-16.01
-71.66%
-9.33
-16.01%
-8.04
-74.87%
-4.60
Total Operating Income As Reported
-16.01
-71.66%
-9.33
-16.01%
-8.04
-74.87%
-4.60
EBITDA
-16.01
-71.68%
-9.32
-16.02%
-8.04
-74.93%
-4.59
Normalized EBITDA
-16.01
-71.68%
-9.32
-16.02%
-8.04
-74.93%
-4.59
Reconciled Depreciation
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
EBIT
-16.01
-71.66%
-9.33
-16.01%
-8.04
-74.87%
-4.60
Net Income
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Pretax Income
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Net Non Operating Interest Income Expense
0.22
-48.86%
0.44
+102.80%
0.22
+685.68%
0.03
Net Interest Income
0.22
-48.86%
0.44
+102.80%
0.22
+685.68%
0.03
Interest Income Non Operating
0.22
-48.86%
0.44
+102.80%
0.22
+685.68%
0.03
Interest Income
0.22
-48.86%
0.44
+102.80%
0.22
+685.68%
0.03
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Net Income From Continuing Operation Net Minority Interest
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Net Income From Continuing And Discontinued Operation
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Net Income Continuous Operations
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Normalized Income
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Net Income Common Stockholders
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Diluted EPS
-1.21
-75.36%
-0.69
-13.11%
-0.61
-74.29%
-0.35
Basic EPS
-1.21
-75.36%
-0.69
-13.11%
-0.61
-74.29%
-0.35
Basic Average Shares
13.01
+1.30%
12.85
-0.51%
12.91
-0.23%
12.94
Diluted Average Shares
13.01
+1.30%
12.85
-0.51%
12.91
-0.23%
12.94
Diluted NI Availto Com Stockholders
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
4.09
-41.47%
6.99
-48.10%
13.48
-50.48%
27.22
Current Assets
4.09
-41.45%
6.99
-48.10%
13.47
-50.49%
27.20
Cash Cash Equivalents And Short Term Investments
4.09
-41.45%
6.99
-48.10%
13.47
-50.49%
27.20
Cash And Cash Equivalents
4.09
-41.45%
6.99
-48.10%
13.47
-50.49%
27.20
Cash Financial
4.09
-41.45%
6.99
-48.10%
13.47
-50.49%
27.20
Total Non Current Assets
0.00
-67.00%
0.01
-40.12%
0.01
-28.63%
0.01
Goodwill And Other Intangible Assets
0.00
-67.00%
0.01
-40.12%
0.01
-28.63%
0.01
Other Intangible Assets
0.00
-67.00%
0.01
-40.12%
0.01
-28.63%
0.01
Total Liabilities Net Minority Interest
1.56
+429.79%
0.29
+11.98%
0.26
-31.74%
0.39
Current Liabilities
1.56
+429.79%
0.29
+11.98%
0.26
-31.74%
0.39
Payables And Accrued Expenses
1.25
+325.76%
0.29
+11.98%
0.26
-31.74%
0.39
Payables
1.18
+359.41%
0.26
+16.06%
0.22
+0.00%
0.22
Accounts Payable
1.18
+359.41%
0.26
+16.06%
0.22
+0.00%
0.22
Current Accrued Expenses
0.08
+99.31%
0.04
-9.44%
0.04
-74.40%
0.16
Current Deferred Liabilities
0.31
—
—
—
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
2.53
-62.18%
6.70
-49.29%
13.21
-50.75%
26.83
Common Stock Equity
2.53
-62.18%
6.70
-49.29%
13.21
-50.75%
26.83
Capital Stock
0.01
+2.37%
0.01
+0.00%
0.01
-2.28%
0.01
Common Stock
0.01
+2.37%
0.01
+0.00%
0.01
-2.28%
0.01
Share Issued
13.15
+2.37%
12.85
+0.00%
12.85
-2.28%
13.15
Ordinary Shares Number
13.15
+2.37%
12.85
+0.00%
12.85
-2.28%
13.15
Additional Paid In Capital
68.67
+20.37%
57.05
+4.35%
54.67
-9.58%
60.47
Retained Earnings
-66.15
-31.35%
-50.36
-21.44%
-41.47
-23.26%
-33.65
Total Equity Gross Minority Interest
2.53
-62.18%
6.70
-49.29%
13.21
-50.75%
26.83
Total Capitalization
2.53
-62.18%
6.70
-49.29%
13.21
-50.75%
26.83
Working Capital
2.53
-62.18%
6.70
-49.30%
13.21
-50.76%
26.82
Invested Capital
2.53
-62.18%
6.70
-49.29%
13.21
-50.75%
26.83
Net Tangible Assets
2.53
-62.18%
6.70
-49.30%
13.21
-50.76%
26.82
Tangible Book Value
2.53
-62.18%
6.70
-49.30%
13.21
-50.76%
26.82
Dueto Related Parties Current
—
—
—
0.00
Interest Payable
—
—
0.22
+0.00%
0.22
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-7.27
-12.16%
-6.48
-4.49%
-6.20
-44.47%
-4.29
Cash Flow From Continuing Operating Activities
-7.27
-12.16%
-6.48
-4.49%
-6.20
-44.47%
-4.29
Net Income From Continuing Operations
-15.79
-77.57%
-8.89
-13.63%
-7.83
-71.21%
-4.57
Depreciation Amortization Depletion
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Amortization Cash Flow
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Depreciation And Amortization
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Amortization Of Intangibles
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Stock Based Compensation
7.25
+205.01%
2.38
+36.37%
1.74
+163.99%
0.66
Change In Working Capital
1.27
+3916.78%
0.03
+125.76%
-0.12
+68.26%
-0.39
Change In Payables And Accrued Expense
0.96
+2944.49%
0.03
+125.76%
-0.12
+68.26%
-0.39
Change In Accrued Expense
0.04
+1052.58%
-0.00
+96.75%
-0.12
-186.37%
0.14
Change In Payable
0.92
+2497.03%
0.04
—
-0.53
Change In Account Payable
0.92
+2497.03%
0.04
0.00
+100.00%
-0.53
Change In Other Working Capital
0.31
—
—
—
Financing Cash Flow
4.37
0.00
+100.00%
-7.54
-365.79%
2.84
Cash Flow From Continuing Financing Activities
4.37
0.00
+100.00%
-7.54
-365.79%
2.84
Net Common Stock Issuance
4.37
0.00
+100.00%
-7.54
0.00
Common Stock Payments
—
0.00
+100.00%
-7.54
0.00
Repurchase Of Capital Stock
—
0.00
+100.00%
-7.54
0.00
Proceeds From Stock Option Exercised
—
—
0.00
-100.00%
3.11
Net Other Financing Charges
—
—
—
-0.28
Changes In Cash
-2.90
+55.28%
-6.48
+52.84%
-13.74
-843.35%
-1.46
Beginning Cash Position
6.99
-48.10%
13.47
-50.49%
27.20
-5.08%
28.66
End Cash Position
4.09
-41.45%
6.99
-48.10%
13.47
-50.49%
27.20
Free Cash Flow
-7.27
-12.16%
-6.48
-4.49%
-6.20
-44.47%
-4.29
Change In Interest Payable
—
—
0.00
-100.00%
0.04
Common Stock Issuance
4.37
0.00
—
3.11
Issuance Of Capital Stock
4.37
0.00
—
3.11
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category